BIOREGULATOR / DIRECT CATALOG PRICING
Vesugen
Vesugen is identified in primary literature as the tripeptide Lys-Glu-Asp (KED). It is a Russian bioregulator trade name, so the catalog name alone does not authenticate the material.
- Format
- Lyophilized research vial
- Listed formats
- 1
- Available now
- 0
- Catalog class
- Bioregulator
- 20 mgPricing by inquiry · AvailableSelect
Pricing, availability, quantity tiers, and member eligibility are checked again when an order is submitted.
TECHNICAL OVERVIEW
Identity first, claims kept in scope.
Vesugen is identified in primary literature as the tripeptide Lys-Glu-Asp (KED). It is a Russian bioregulator trade name, so the catalog name alone does not authenticate the material.
The bioregulator classification supports catalog navigation; it does not establish efficacy, safety, approval, human use, or equivalence to a material used in a cited study.
SPECIFICATIONS
- Material class
- Bioregulator
- Physical format
- Lyophilized vial
- Research status
- Research purposes only
- Commerce status
- Contact for current availability
PLAIN-LANGUAGE RESEARCH SNAPSHOT
What researchers have actually studied.
Vesugen is identified in primary literature as the tripeptide Lys-Glu-Asp (KED). It is a Russian bioregulator trade name, so the catalog name alone does not authenticate the material.
- Research covered
- KED was tested in human embryonic fibroblast cultures for differentiation-factor expression and in animal-derived vascular endothelial cultures for proliferation-related endpoints. A small human study combined Vesugen with Pinealon and measured biological-age-related markers.
- Important limit
- The human report is small and combined, so effects cannot be attributed to Vesugen alone. Most evidence is cell-based and from a narrow investigator network. Sequence and purity of catalog material require independent analysis.
FACTUAL FAQ
Vesugen catalog questions
What formats are currently listed?
20 mg. Current price and stock state appear above.
What did researchers study?
KED was tested in human embryonic fibroblast cultures for differentiation-factor expression and in animal-derived vascular endothelial cultures for proliferation-related endpoints. A small human study combined Vesugen with Pinealon and measured biological-age-related markers.
What is the most important evidence limit?
The human report is small and combined, so effects cannot be attributed to Vesugen alone. Most evidence is cell-based and from a narrow investigator network. Sequence and purity of catalog material require independent analysis.
How should this listing be interpreted?
It is a research-material catalog listing, not medical guidance, a dosage recommendation, a safety or efficacy claim, or evidence of regulatory approval.
Where can I review related scientific references?
Use the PSC research library to locate general and compound-related source material. Open related research references →
